Tenax Therapeutics (TENX) Reiterated at Overweight by Cantor Fitzgerald: Ph3 Data in Q3
Tweet Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $35.00 price target on Tenax Therapeutics (NASDAQ: TENX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
